Ligand Pharmaceuticals (LGND) Earnings Date, Estimates & Call Transcripts

$232.30 +3.94 (+1.73%)

Closing price 05/5/2026 04:00 PM Eastern

Extended Trading

$232.12 -0.18 (-0.08%)

As of 05/5/2026 07:31 PM Eastern

Ligand Pharmaceuticals Earnings Summary

Ligand Pharmaceuticals posted Q4 2025 earnings on February 26, 2026, reporting an EPS of $2.02, which topped the consensus estimate of $1.46 by $0.56. Quarterly revenue rose 39.5% year-over-year to $59.67 million, above analysts' expectations of $55.59 million. With a trailing EPS of $5.83 and a P/E Ratio of 39.85, Ligand Pharmaceuticals' earnings are expected to grow 17.75% next year, from $7.10 to $8.36 per share.

Upcoming Earnings Date: May. 6Estimated
Consensus EPS (Feb. 26): $1.46
Actual EPS (Feb. 26): $2.02 Beat By $0.56
Actual Revenue (Feb. 26): $59.67M

Q4 2025 Earnings Resources

LGND Upcoming Earnings

Ligand Pharmaceuticals' Q1 2026 earnings is estimated for Wednesday, May 6, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 7, 2026 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Slide Deck

Full Screen Slide Deck

Get Ligand Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ligand Pharmaceuticals and other key companies, straight to your inbox.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LGND Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LGND Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ligand Pharmaceuticals Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2026	1	$1.19	$1.19	$1.19
Q3 2026	1	$1.67	$1.67	$1.67
Q4 2026	1	$1.75	$1.75	$1.75

Ligand Pharmaceuticals Earnings History by Quarter

Time Frame

Start Date

End Date

Export

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue	Details
5/6/2026 (Estimated)	-	-	-	-	-	-	-	-
2/26/2026	Q4 2025	$1.46	$2.02	+$0.56	$2.12	$55.59M	$59.67M
11/6/2025	Q3 2025	$1.96	$3.09	+$1.13	$5.68	$58.71M	$86.89M
8/7/2025	Q2 2025	$1.54	$1.60	+$0.06	$0.24	$43.87M	$47.63M
5/8/2025	Q1 2025	$1.23	$1.33	+$0.10	-$2.21	$37.84M	$45.33M
8/6/2024	Q2 2024	$1.06	$1.40	+$0.34	$4.72	$33.04M	$41.50M
5/7/2024	Q1 2024	$0.83	$3.84	+$3.01	-$3.15	$27.92M	$30.90M

Data powered by Fiscal.ai.

Ligand Pharmaceuticals Earnings - Frequently Asked Questions

: Ligand Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 6th, 2026 based off last year's report dates. Learn more on LGND's earnings history.
: Ligand Pharmaceuticals issued an update on its FY 2026 earnings guidance on Monday, April, 27th. The company provided earnings per share guidance of 8.500-9.500 for the period, compared to the consensus earnings per share estimate of 8.000. The company issued revenue guidance of $270.0 million-$310.0 million, compared to the consensus revenue estimate of $267.5 million.
: In the previous quarter, Ligand Pharmaceuticals (NASDAQ:LGND) reported $2.02 earnings per share (EPS) to beat the analysts' consensus estimate of $1.46 by $0.56. Learn more on analysts' earnings estimate vs. LGND's actual earnings.
: The conference call for Ligand Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call
: The conference call transcript for Ligand Pharmaceuticals' latest earnings report can be read online.
Read Transcript
: Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded annual revenue of $268.09 million.
: Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded net income of $124.45 million. LGND has generated $5.83 earnings per share over the last four quarters.
: Ligand Pharmaceuticals (NASDAQ:LGND) has a trailing price-to-earnings ratio of 39.85 and a forward price-to-earnings ratio of 32.72. The price/earnings-to-growth ratio is 1.43.
: Ligand Pharmaceuticals' earnings are expected to grow from $7.10 per share to $8.36 per share in the next year, which is a 17.75% increase.

More Earnings Resources from MarketBeat

Related Companies

Earnings Tools

Latest Articles

This page (NASDAQ:LGND) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Earnings Date, Estimates & Call Transcripts